Does Rallies show Form 4 insider transactions for XENE?

Yes. Rallies tracks XENE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is XENE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for XENE. It does not provide personalized investment advice.

XENE (Xenon Pharmaceuticals Inc) Stock Analysis - Insider Trades

Xenon Pharmaceuticals Inc (XENE) is a publicly traded Healthcare sector company. As of May 20, 2026, XENE trades at $54.67 with a market cap of $5.19B and a P/E ratio of -12.52. XENE moved +1.17% today. Year to date, XENE is +30.84%; over the trailing twelve months it is +73.97%. Its 52-week range spans $26.74 to $63.95. Analyst consensus is strong buy with an average price target of $78.37. Rallies surfaces XENE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading XENE stock inside the company?

Recent XENE insider activity includes KENNEY CHRISTOPHER JOHN sold 1.41K, DiFabio Andrea sold 1.34K, MORTIMER IAN sold 7.31K, KENNEY CHRISTOPHER JOHN sold 2.77K, and DiFabio Andrea sold 2.61K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

XENE Key Metrics

Key financial metrics for XENE
Metric	Value
Price	$54.67
Market Cap	$5.19B
P/E Ratio	-12.52
EPS	$-4.36
Dividend Yield	0.00%
52-Week High	$63.95
52-Week Low	$26.74
Volume	860.40K
Avg Volume	0
Revenue (TTM)	$7.50M
Net Income	$-345.91M
Gross Margin	0.00%

Recent XENE Insider Trades

KENNEY CHRISTOPHER JOHN sold 1.41K (~$77.87K) on Mar 13, 2026.
DiFabio Andrea sold 1.34K (~$74.11K) on Mar 13, 2026.
MORTIMER IAN sold 7.31K (~$403.58K) on Mar 13, 2026.
KENNEY CHRISTOPHER JOHN sold 2.77K (~$166.56K) on Mar 10, 2026.
DiFabio Andrea sold 2.61K (~$156.70K) on Mar 10, 2026.

Latest XENE News

Xenon Secures $1.3B Cash Runway, Eyes Q3 2026 NDA After 53.2% Seizure Reduction — May 7, 2026
Xenon rises as Phase 3 azetukalner focus returns ahead of May catalysts — May 4, 2026
Xenon Pharmaceuticals Secures US$747.5M Financing After Phase 3 Success of AZK — May 1, 2026
Xenon climbs as Phase 3 azetukalner momentum builds and funding optionality stays in focus — Apr 29, 2026
Xenon slips as investors sell the news after detailed Phase 3 azetukalner data — Apr 20, 2026

XENE Analyst Consensus

19 analysts cover XENE: 0 strong buy, 19 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $78.37.

Common questions about XENE

Who is trading XENE stock inside the company?: Recent XENE insider activity includes KENNEY CHRISTOPHER JOHN sold 1.41K, DiFabio Andrea sold 1.34K, MORTIMER IAN sold 7.31K, KENNEY CHRISTOPHER JOHN sold 2.77K, and DiFabio Andrea sold 2.61K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for XENE?: Yes. Rallies tracks XENE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is XENE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for XENE. It does not provide personalized investment advice.